Recent advances in neuroprotection for treating traumatic brain injury

Expert Opinion on Investigational Drugs

Volumn 15, Issue 11, 2006, Pages 1371-1381

  Cernak, Ibolja ^a  

^a JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY   (United States)

Author keywords

Nanotechnology; Neuroprotection; Traumatic brain injury

Indexed keywords

BARBITURIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBON NANOTUBE; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYCLO(HISTIDYLPROLINE); CYCLOOXYGENASE 2 INHIBITOR; DEXANABINOL; FLAVOPIRIDOL; GLUCOCORTICOID; GLUTAMATE RECEPTOR ANTAGONIST; MAGNESIUM CHLORIDE; MAGNESIUM SALT; MAGNESIUM SULFATE; MANNITOL; MRZ 2 576; NERAMEXANE; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; OLOMOUCINE; POTASSIUM; PROGESTERONE; ROSCOVITINE; SCAVENGER; SODIUM; SODIUM CHLORIDE; STEROID; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG; NEW DRUG;

ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN DECOMPRESSION; BRAIN EDEMA; BRAIN FUNCTION; BRAIN ISCHEMIA; BRAIN TOMOGRAPHY; CELL CYCLE REGULATION; CLINICAL TRIAL; CRANIECTOMY; DEMYELINATION; DISEASE SEVERITY; DIURESIS; DRUG DELIVERY SYSTEM; DRUG INFUSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLASGOW COMA SCALE; HUMAN; HYPOTENSION; HYPOVOLEMIA; INDUCED HYPOTHERMIA; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; KIDNEY FAILURE; NANOTECHNOLOGY; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRACTICE GUIDELINE; PREMATURITY; QUALITY OF LIFE; REBOUND; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; STEM CELL TRANSPLANTATION; STROKE; SUBARACHNOID HEMORRHAGE; THERAPEUTIC HYPERVENTILATION; TRAUMATIC BRAIN INJURY; TREATMENT FAILURE; UPREGULATION; ANIMAL; BRAIN INJURY; PATHOPHYSIOLOGY;

ANIMALS; BRAIN INJURIES; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 33750132412     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.11.1371     Document Type: Review

References (105)

1. BRUNS J Jr, HAUSER WA: The epidemiology of traumatic brain injury: a review. Epilepsia (2003) 44(Suppl. 10):2-10.
2. CENTER FOR DISEASE CONTROL AND PREVENTION: Incidence rates of hospitalization related to traumatic brain injury-12 states, 2002. MMWR Morb. Mortal. Wkly Rep. (2006) 55(8):201-204.
3. TOLIAS CM, BULLOCK MR: Critical appraisal of neuroprorection trials in head injury: what have we learned? NeuroRx (2004) 1(1):71-79.
4. VINK R, VAN DEN HEUVEL C: Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury. Expert Opin. Investig. Drugs (2004) 13(10):1263-1274.
5. CERNAK I: Animal models of head trauma. NeuroRx (2005) 2(3):410-422.
6. FADEN AI: Neuroprotection and traumatic brain injury: the search continues. Arch. Neurol. (2001) 58(10):1553-1555.
7. NARAYAN RK, MICHEL ME, ANSELL B et al.: Clinical trials in head injury. J. Neurotrauma (2002) 19(5):503-557.
8. EDWARDS P, ARANGO M, BALICA L et al.: Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet (2005) 365(9475):1957-1959.
9. ROBERTS I: Barbiturates for acute traumatic brain injury. Cochrane Database Syst. Rev. (2000) 2:CD000033.
10. MORRIS SH, KNEVETT S, LERNER EG, BINDMAN LJ: Group I mGluR agonist DHPG facilitates the induction of LTP in rat prelimbic cortex in vitro. J. Neurophysiol. (1999) 82(4):1927-1933.
11. YOUNG B, RUNGE JW, WAXMAN KS et al.: Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA (1996) 276(7):538-543.
12. THE EUROPEAN STUDY GROUP ON NIMODIPINE IN SEVERE HEAD INJURY: A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J. Neurosurg. (1994) 80(5):797-804.
13. LANGHAM J, GOLDFRAD C, TEASDALE G, SHAW D, ROWAN K: Calcium channel blockers for acute traumatic brain injury. Cochrane Database Syst. Rev. (2003) 4:CD000565.
14. BIEGON A, JOSEPH AB: Development of HU-211 as a neuroprotectant for ischemic brain damage. Neurol. Res. (1995) 17(4):275-280.
15. BAYIR H, CLARK RS, KOCHANEK PM: Promising strategies to minimize secondary brain injury after head trauma. Crit. Care Med. (2003) 31(Suppl. 1):S112-S117.
16. SHOHAMI E, NOVIKOV M, BASS R: Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res. (1995) 674(1):55-62.
17. SHOHAMI E, GALLILY R, MECHOULAM R, BASS R, BEN-HUR T: Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J. Neuroimmunol. (1997) 72(2):169-177.
18. KNOLLER N, LEVI L, SHOSHAN I et al.: Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, Phase II clinical trial. Crit. Care Med. (2002) 30(3):584-554.
19. MAAS A, MURRAY G, HENNEY HI et al.: Efficacy and safety of dexanabinol in severe traumatic brain injury: results of Phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. (2006) 5:38-45.
20. VINK R, CERNAK I: Regulation of intracellular free magnesium in central nervous system injury. Front. Biosci. (2000) 5:D656-D665.
21. VINK R, O'CONNOR CA, NIMMO AJ, HEATH DL: Magnesium attenuates persistent functional deficits following diffuse traumatic brain injury in rats. Neurosci. Lett. (2003) 336(1):41-44.
22. HEATH DL, VINK R: Magnesium sulphate improves neurologic outcome following severe closed head injury in rats. Neurosci. Lett. (1997) 228(3):175-178.
23. MUIR KW: New experimental and clinical data on the efficacy of pharmacological magnesium infusions in cerebral infarcts. Magnes. Res. (1998) 11(1):43-56.
24. MAUSKOP A, ALTURA BT, CRACCO RQ, ALTURA BM: Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache (1996) 36(3):154-160.
25. MUIR KW, LEES KR, FORD I, DAVIS S, INTRAVENOUS MAGNESIUM EFFICACY IN STROKE (IMAGES) STUDY INVESTIGATORS: Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomized controlled trial. Lancet (2004) 36(9407):439-435.
26. BOET R, MEE E: Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery (2000) 47(3):602-606 (Discussion 606-607).
27. VEYNA RS, SEYFRIED D, BURKE DG et al.: Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J. Neurosurg. (2002) 96(3):510-514.
28. McKEE JA, BREWER RP, MACY GE et al.: Magnesium neuroprorection is limited in humans with acute brain injury. Neurocrit. Care (2005) 2(3):342-351.
29. CHAN MT, BOET R, NG SC, POON WS, GIN T. Magnesium sulfate for brain protection during temporary cerebral artery occlusion. Acta Neurochir. Suppl. (2005) 95:107-111.
30. VAN DEN BERGH WM, ALGRA A, VAN KOOTEN F, RINKEL GJ, MASH STUDY GROUP: Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke (2005) 36(5):1011-1015.
31. GHABRIEL MN, THOMAS A, VINK R: Magnesium restores altered aquaporin-4 immunoreactiviry following traumatic brain injury to a pre-injury state. Arta Neurochir. Suppl. (2006) 96:402-406.
32. HOANE MR: Treatment with magnesium improves reference memory while reducing GFAP expression following traumatic brain injury. J. Neurotrauma (2005) 22(7):783-792.
33. TEASDALE GM, MAAS A, IANNOTTI F, OHMAN J, UNTERBERG A: Challenges in translating the efficacy of neuroprotective agents in experimental models into knowledge of clinical benefits in head injured patients. Acta Neurochir. Suppl. (Wien) (1999) 73:111-116.
34. MAAS AI: Neuroprotective agents in traumatic brain injury. Expert Opin. Investig. Drugs (2001) 10(4):753-767.
35. O'CONNOR CA, CERNAK I, VINK R: Interaction between anesthesia, gender, and functional outcome task following diffuse traumatic brain injury in rats. J. Neurotrauma (2003) 20(6):533-541.
36. DOPPENBERG EM, CHOI SC, BULLOCK R: Clinical trials in traumatic brain injury. What can we learn from previous studies? Ann. NY Acad. Sci. (1997) 825:305-322.
37. FADEN AI: Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr. Opin. Neurol. (2002) 15(6):707-712.
38. ZHAO H, YENARI MA, SAPOLSKY RM, STEINBERG GK: Mild postischemic hypothermia. prolongs the time window for gene therapy by inhibiting cytochrome C release. Stroke (2004) 35(2):572-577.
39. INAMASU J, SUGA S, SATO S et al.: Postischemic hypothermia attenuates apoptotic cell death in transient focal ischemia in rats. Acta Neurochir. Suppl. (2000) 76:525-527.
40. HASHIGUCHI N, SHIOZAKI T, OGURA H et al.: Mild hypothermia reduces expression of heat shock protein 60 in leukocytes from severely head-injured patients. J. Trauma (2003) 55(6):1054-1060.
41. ADELSON PD, RAGHEB J, MUIZELAAR JP et al.: Phase II clinical trial of moderate hypothermia after severe traumatic brain injury in children. Neurosurgery (2004) 56:740-754.
42. SAHUQUILLO J, ARIKAN F: Decompressive craniectomy for the treatment of refractory high intracranial pressure in traumatic brain injury. Cochrane Database Syst. Rev. (2006) 1:CD003983.
43. CLIFTON GL, MILLER ER, CHOI SC et al.: Lack of effect of induction of hypothermia after acute brain injury. N. Engl. J. Med. (2001) 344(8):556-563.
44. SEPPELT I: Hypothermia does not improve outcome from traumatic brain injury. Crit. Care Resusc. (2005) 7(3):233-237.
45. SIGNORINI DF, ANDREWS PJ, JONES PA, WARDLAW JM, MILLER JD: Adding insult to injury: the prognostic value of early secondary insults for survival after traumatic brain injury. J. Neurol. Neurosurg. Psychiatry (1999) 66(1):26-31.
46. CZOSNYKA M, GUAZZO E, WHITEHOUSE M et al.: Significance of intracranial pressure waveform analysis after head injury. Acta Neurochir. (Wien) (1996) 138(5):531-541 (Discussion 541-532).
47. JOURDAN C, CONVERT J, MOTTOLESE C et al.: Evaluation of the clinical benefit of decompression hemicraniectomy in intracranial hypertension not controlled by medical treatment. Neurochirurgie (1993) 39(5):304-310.
48. BRAIN TRAUMA FOUNDATION: Guidelines for the Management of Severe Head Injury. Brain Trauma Foundation, New York, USA (1995).
49. COOPER PR, ROVIT RL, RANSOHOFF J: Hemicraniectomy in the treatment of acute subdural hematoma: a re-appraisal hemicraniecromy in the treatment of acute subdural hematoma. Surg. Neurol, (1976) 5:25-28.
50. MAKINO H, YAMAURA A: Assessment of outcome following large decompressive craniectomy in management of serious cerebral contusion. A review of 207 cases. Acta Neurochir. Suppl. (1976) 28(1):193-194.
51. TAYLOR A, BUTT W, ROSENFELD J et al.: A randomized trial of very early decompressive craniectomy in children with traumatic brain injury and sustained intracranial hypertension. Childs Nerv. Syst. (2001) 17(3):154-162.
52. BERGER MS, PITTS LH, LOVELY M, EDWARDS MS, BARTKOWSKI HM: Outcome from severe head injury in children and adolescents. J. Neurosurg. (1985) 62(2):194-199.
53. FELDERHOFF-MUESER U, IKONOMIDOU C: Mechanisms of neurodegeneration after paediatric brain injury. Curr. Opin. Neurol. (2000) 13(2):141-145.
54. KIMELBERG HK: Current concepts of brain edema. Review of laboratory investigations. J. Neurosurg. (1995) 83(6):1051-1059.
55. JOO F, KLATZO I: Role of cerebral endothelium in brain oedema. Neurol. Res. (1989) 11(2):67-75.
56. DEMPSEY RJ, BASKAYA MK, DOGAN A: Attenuation of brain edema, blood-brain barrier breakdown, and injury volume by ifenprodil, a polyamine-site N-methyl-D-aspartate receptor antagonist, after experimental traumatic brain injury in rats. Neurosurgery (2000) 47(2):399-404.
57. 2 receptor antagonist on brain edema formation and ischemic tissue darnage in focal cerebral ischemia. Acta Neurochir. Suppl. (2003) 86:205-207.
58. SHIGEMORI Y, KATAYAMA Y, MORI T, MAEDA T, KAWAMATA T: Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochi. Suppl. (2006) 96:130-133.
59. AMIRY-MOGHADDAM M, OTSUKA T, HURN PD et al.: An α-syntrophin-dependent pool ofAQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc. Natl. Acad. Sci. USA (2003) 100(4):2106-2111.
60. KLEINDIENST A, FAZZINA G, AMORINI AM et al.: Modulation of AQP4 expression by the protein kinase C activator, phorbol myristate acetate, decreaes ischemia-induced brain edema. Acta Neurochir. Suppl. (2006) 96:393-397.
61. NIMMO AJ, CERNAK I, HEATH DL et al.: Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides (2004) 38(1):40-47.
62. VINK R, DONKIN JJ, CRUZ MI, NIMMO AJ, CERNAK I: A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J. Am. Coll. Nutr. (2004) 23(5):538S-540S.
63. WAKAI A, ROBERTS I, SCHIERHOUT G: Mannitol for acute traumatic brain injury. Cochrane Database Syst. Rev. (2005) 4:CD001049.
64. DOYLE JA, DAVIS DP, HOYT DB: The use of hypertonic saline in the treatment of traumatic brain injury. J. Trauma (2001) 50(2):367-383.
65. RABINSTEIN AA: Treatment of cerebral edema. Neurologist (2006) 12(2):59-73.
66. FRESHMAN SP, BATTISTELLA FD, MATTEUCCI M, WISNER DH: Hypertonic saline (7.5%) versus mannitol: a comparison for treatment of acute head injuries. J. Trauma (1993) 35(3):344-348.
67. PINTO FC, CAPONE-NETO A, PRIST R, E SILVA MR, POLI-DE-FIGUEIREDO LF: Volume replacement with lactated Ringer's or 3% hypertonic saline solution during combined experimental hemorrhagic shock and traumatic brain injury. J. Trauma (2006) 60(4):758-763 (Discussion 763-754).
68. COOPER DJ, MYLES PS, McDERMOTT FT et al.: Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA (2004) 291(11):1350-1357.
69. FRENCH LA, GALICICH JH: The use of steroids for control of cerebral edema. Clin. Neurosurg. (1964) 10:212-223.
70. GHAJAR J, HESDORFFER DC: Steroids CRASH out of head-injury treatment. Lancet Neurol. (2004) 3(12):708.
71. GONG Y, XI GH, KEEP RF, HOFF JT, HUA Y. Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. Acta Neurochir. Suppl. (2005) 95:389-392.
72. WANG F, FENG XC, LI YM, YANG H, MA TH: Aquaporins as potential drug targets. Acta Pharmacol. Sin. (2006) 27(4):395-340.
73. 2 receptor inhibition after focal cerebral ischemia in rats. Neurochem. Int. (2006) 49(5):442-447.
74. SINGH M: Progesterone-induced neuroprotection. Endocrine (2006) 29(2):271-274.
75. STEIN DG: The case for progesterone. Ann. NY Acad. Sci. (2005) 1052:152-169.
76. O'CONNOR CA, CERNAK I, VINK R: Both estrogen and progesterone attenuate edema formation following diffuse traumatic brain injury in rats. Brain Res. (2005) 1062(1-2):171-174.
77. CUTLER SM, VANLANDINGHAM JW, MURPHY AZ, STEIN DG: Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury. Pharmacol. Biochem. Behav. (2006) 24:24.
78. ROBERTSON CL, PUSKAR A, HOFFMAN GE et al.: Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp. Neurol. (2006) 197(1):235-243.
79. ROOF RL, HOFFMAN SW, STEIN DG: Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol. Chem. Neuropathol. (1997) 31(1):1-11.
80. DJEBAILI M, HOFFMAN SW, STEIN DG: Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience (2004) 123(2):349-359.
81. WRIGHT DW, RITCHIE JC, MULLINS RE, KELLERMANN AL, DENSON DD: Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J. Clin. Pharmacol. (2005) 45(6):640-648.
82. SHOUTEN JW, FULP CT, ROYO NC et al.: A review and rationale for the use of cellular transplantation as a therapeutic strategy for traumatic brain injury. J. Neurotrauma (2004) 21(11):1501-1538.
83. JOHANSSON B, GRABOWSKI M: Functional recovery after brain infarction: plasticity and neural transplantation. Brain Pathol. (1994) 4:85-95.
84. BARINAGA M: Fetal neuron grafts pave the way for stem cell therapies. Science (2000) 287:1421-1422.
85. TROJANOSWKI JQ, KLEPPNER SR, HARTLEY RS et al.: Transfectable and transplantable postmitotic human neurons: a potential 'platform' for gene therapy of nervous system diseases. Exp. Neural. (1997) 144(1):92-97.
86. KONDZIOLKA D, STEINBERG GK, WECHSLER L et al.: Neurotransplantation for patients with subcortical motor stroke: a Phase II randomized trial. J. Neurosurg. (2005) 10:38-45.
87. ZHANG S-C: Embryonic stem cells for neural replacement therapy: prospects and challenges. J. Hematother. Stem Cel/Res. (2003) 12:625-634.
88. NGUYEN MD, MUSHYNSKI WE, JULIEN JP: Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ. (2002) 9(12):1294-1306.
89. DI GIOVANNI S, MOVSESYAN V AHMED F et al.: Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Prot. Natl. Acad. Sci. USA (2005) 102(23):8333-8338.
90. CERNAK I, STOICA B, BYRNES KR, DI GIOVANNI S, FADEN AI: Role of the cell cycle in the parhobiology of central nervous system trauma. Cell Cycle (2005) 4(9):1286-1293.
91. VERDAGUER E, JORDA EG, ALVIRA D et al.: Inhibition of multiple pathways accounts for the antiapoptotic effects of flavopiridol on potassium withdrawal-induced apoptosis in neurons. J. Mol. Neurosci. (2005) 26(1):71-84.
92. FADEN AI: Neuropeptides and central nervous system injury. Clinical implications. Arch. Neurol. (1986) 43(5):501-504.
93. FADEN AI, KNOBLACH SM, CERNAK I et al.: Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J. Cereb. Blood Flow Metab. (2003) 23(3):342-354.
94. FADEN AI, KNOBLACH SM, MOVSESYAN VA, LEA PMT, CERNAK I. Novel neuroprotective tripeptides and dipeptides. Ann. NY Acad. Sci. (2005) 1053:472-481.
95. MINAMI M, KATAYAMA T, SATOH M: Brain cytokines and chemokines: roles in ischemic injury and pain. J. Pharmacol. Sci. (2006) 100(5):461-470.
96. LUCAS SM, ROTHWELL NJ, GIBSON RM: The role of inflammation in CNS injury and disease. Br. J. Pharmacol. (2006) 147(Suppl. 1):S232-S240.
97. CERNAK I, O'CONNOR C, VINK R: Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Exp. Brain Res. (2002) 147(2):193-199.
98. KAWANO T, ANRATHER J, ZHOU P et al.: Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. (2006) 12(2):225-229.
99. SEWELL DL, NACEWICZ B, LIU F et al.: Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol. (2004) 155:55-63.
100. VINK R, YOUNG A, BENNETT CJ et al.: Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir. Suppl. (2003) 86:257-260.
101. SILVA GA: Neuroscience nanotechnology: progress, opportunities and challenges. Nat. Rev. Neurosci. (2006) 7(1):65-74.
102. ELLIS-BEHNKE RG, LIANG YX, YOU SW et al.: Nano neuro knitting: peptide nanofiber scaffold for brain repair mid axon regeneration with functional return of vision. Proc. Natl. Acad. Sci. USA (2006) 103(13):5054-5059.
103. JOHANSSON F, CARLBERG P, DANIELSEN N, MONTELIUS L, KANJE M: Axonal outgrowth on nano-imprinted patterns. Biomaterials (2006) 27(8):1251-1258.
104. LOVAT V, PANTAROTTO D, LAGOSTENA L et al.: Carbon nanotube substrates boost neuronal electrical signaling. Nano Lett. (2005) 5(6):1107-1110.
105. KREUTER J: Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. (2004) 4(5):484-488.